Asia-Pacific Contract Research Organization Market

Asia-Pacific Contract Research Organization Market Analysis

The Asia-Pacific Contract Research Organization Market size is estimated at USD 18.94 billion in 2025, and is expected to reach USD 31.10 billion by 2030, at a CAGR of 10.43% during the forecast period (2025-2030).

Research and development activities are on the rise, clinical trials are proliferating, and outsourcing is becoming increasingly popular. These trends are poised to fuel market growth in the coming years. A significant factor driving this growth is the Asia-Pacific region's vast and varied patient population, which serves as a rich resource for clinical trials. Moreover, Asia-Pacific boasts a pool of skilled medical professionals and offers operational costs that are more economical than those in Western nations. This cost advantage, combined with the availability of expertise, positions the region as an attractive destination for pharmaceutical and biotechnology companies seeking to optimize their research and development operations.

Highlighting this trend, Freyr Solutions, an United States based CRO, established a subsidiary in Japan in April 2023, signaling its strategic intent to enhance business development and create employment opportunities in the country. Similarly, in July 2023, Citeline, a company specializing in clinical trial intelligence, entered into a strategic partnership with Clinrol, a clinical trial recruitment firm, to strengthen and expand patient recruitment capabilities for upcoming clinical trials across Asia-Pacific. These strategic initiatives by key market players underscore the region's growing prominence as a hub for clinical research and are expected to significantly contribute to market growth.

In Asia-Pacific, government backing for CRO activities is anticipated to further fuel market expansion. For instance, in June 2023, the Department of Biotechnology (DBT) in India reported that Gennova Biopharmaceuticals Ltd's Omicron-specific mRNA booster vaccine, developed using advanced platform technology, received Emergency Use Authorization (EUA) from the Drug Control General of India (DCGI). This development highlights the region's commitment to fostering innovation and supporting the growth of the clinical research ecosystem. Given these advancements, coupled with increased government support and strategic initiatives by major industry players, the Asia-Pacific market is well-positioned for substantial growth over the forecast period.

However, the industry faces a critical challenge: the shortage of skilled professionals, which could act as a constraint on the market's expansion potential.

Asia-Pacific Contract Research Organization Market Trends

The Infectious Diseases Segment is Expected to Witness Positive Growth Over the Forecast Period

Infectious diseases are mainly caused by a pathogen or its toxic product, transmitted from a person or animal or an infected non-living object to a susceptible host. Factors such as an increase in infectious diseases across Asia-Pacific, a rise in demand for vaccine development to treat infectious diseases, and an increase in facility expansions by the key CROs to manufacture drugs for infectious diseases are anticipated to drive the segment growth over the forecast period.

The increase in infectious diseases across Asia-Pacific urges the development of various vaccines and drugs, which is expected to drive the market growth over the forecast period. For instance, as per the provisional cases of notifiable diseases by prefecture in Japan published by the National Institute of Infectious Diseases, Japan, as of April 2024, 3.64 thousand cases of tuberculosis and 140 instances of Hepatitis E were reported in Japan as a cumulative prevalence in 2024. As a result, the high prevalence of infectious diseases is anticipated to drive market growth over the forecast period.

The presence of key market players and their strategic expansions and agreements are likely to drive market growth over the forecast period. For instance, in January 2023, Southern Star Research, an Australian CRO specializing in clinical trial acceleration, expanded into South Korea to offer clients access to medical and clinical products and patients in the region. Such market player activities are also anticipated to boost the growth of the Asia-Pacific contract manufacturing market over the forecast period.

Thus, owing to the rise in infectious disease in Asia-Pacific and the surge in strategic activities by the key players, the market is likely to witness significant growth over the forecast period.

India is Expected to Witness a Significant Growth Over the Forecast Period

India's market is poised for substantial growth, driven by a surge in chronic diseases, heightened clinical trial activities, and the active involvement of major players. For instance, the Indian Council of Medical Research-National Cancer Registry Programme (ICMR-NCRP) reported in March 2024 that cancer cases in India are projected to climb from 1.46 million in 2022 to 1.57 million by 2025. This anticipated uptick in cancer cases is set to amplify the demand for biopharma drugs, thereby creating significant opportunities for market expansion and revenue generation within the healthcare and pharmaceutical industries.

Furthermore, the market is expected to benefit from a series of strategic initiatives, including product launches, increased investments, and facility expansions, which are likely to strengthen the competitive landscape and enhance operational capabilities.

For instance, Eurofins, in January 2023, launched a facility on its Hyderabad campus, signaling its commitment to expanding its footprint in India's pharmaceutical market. Similarly, in April 2023, Sai Life Sciences, a leading India-based contract research organization (CRO), inaugurated SSRL, a specialized research hub for Schrödinger, at its Hyderabad R&D Campus, showcasing its focus on fostering innovation and collaboration.

Additionally, in May 2023, Aurigene Pharmaceutical Services Limited (Aurigene) initiated the construction of a state-of-the-art development and manufacturing facility at Genome Valley, Hyderabad, dedicated to therapeutic proteins, antibodies, and viral vectors. These strategic expansions by key CROs and pharmaceutical companies are expected to drive market growth by enhancing research and development capabilities, improving service offerings, and meeting the growing demand for advanced therapeutic solutions.

In light of the rising prevalence of chronic diseases, the expanding footprint of CROs, and increased clinical trial investments by key players, India's market trajectory appears robust, with significant growth potential over the forecast period. These developments are likely to position India as a critical hub for pharmaceutical innovation and biopharmaceutical advancements.

Asia-Pacific Contract Research Organization Industry Overview

The Asia-Pacific contract research organization market is semi-consolidated in nature due to the presence of several companies operating globally and regionally. The key companies are involved in various strategic activities such as market expansions, mergers, and acquisitions to enhance their overall market growth. A few of the major companies in the market are Charles River Laboratories, Syneos Health, Laboratory Corporation of America Holdings, WuXi Pharmatech, and ArisGlobal, among others.

Asia-Pacific Contract Research Organization Market Leaders

Asia-Pacific Contract Research Organization Market News

• March 2024: India-based Veeda Clinical Research Limited, a full-service contract research organization (CRO), acquired Heads, a full-service contract research organization that focused on conducting clinical trials in oncology. With this acquisition, Veeda enters the global CROs with integrated capabilities to extend contract research services from discovery to clinical development.
• August 2023: ECLEVAR MEDTECH, a French-based CRO specializing in medtech industry, entered a partnership with Micron, a Japanese domestic CRO, to offer services to both Japanese medtech manufacturers who want to expand their business overseas and foreign medtech manufacturers who want to enter the Japanese market.